Protocol Ledger

NCT06065748 · Phase III · ACTIVE NOT RECRUITING

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy

Interventional Phase III clinical trial protocol NCT06065748 sponsored by Roche / Genentech in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-12-11 Enrollment: 1,050 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06065748
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,050 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06065748
Protocol FieldVerified Registry Value
NCT IdentifierNCT06065748
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment1,050 participants (ESTIMATED)
Registered Start Date2023-12-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI